BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochemical and Biophysical Research Communications 2018;507:330-6. [DOI: 10.1016/j.bbrc.2018.11.035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu S, Imani S, Deng Y, Pathak JL, Wen Q, Chen Y, Wu J. Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance. Onco Targets Ther 2020;13:6037-50. [PMID: 32606809 DOI: 10.2147/OTT.S256708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Shi LZ, Bonner JA. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis. Int J Mol Sci 2021;22:12295. [PMID: 34830176 DOI: 10.3390/ijms222212295] [Reference Citation Analysis]
3 Liu S, Wang Z, Li S. Interferon Regulatory Factor Family Genes: At the Crossroads between Immunity and Head and Neck Squamous Carcinoma. Disease Markers 2022;2022:1-19. [DOI: 10.1155/2022/2561673] [Reference Citation Analysis]
4 Betzler AC, Theodoraki MN, Schuler PJ, Döscher J, Laban S, Hoffmann TK, Brunner C. NF-κB and Its Role in Checkpoint Control. Int J Mol Sci 2020;21:E3949. [PMID: 32486375 DOI: 10.3390/ijms21113949] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
5 Hwang BJ, Tsao LC, Acharya CR, Trotter T, Agarwal P, Wei J, Wang T, Yang XY, Lei G, Osada T, Lyerly HK, Morse MA, Hartman ZC. Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. J Immunother Cancer 2022;10:e003721. [PMID: 35361727 DOI: 10.1136/jitc-2021-003721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chu Z, Gu L, Hu Y, Zhang X, Li M, Chen J, Teng D, Huang M, Shen CH, Cai L, Yoshida T, Qi Y, Niu Z, Feng A, Geng S, Frederick DT, Specht E, Piris A, Sullivan RJ, Flaherty KT, Boland GM, Georgopoulos K, Liu D, Shi Y, Zheng B. STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. Nat Commun 2022;13:1859. [PMID: 35388001 DOI: 10.1038/s41467-022-29541-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang Y, Chen‐mayfield T, Li Z, Younis MH, Cai W, Hu Q. Harnessing DNA for Immunotherapy: Cancer, Infectious Diseases, and Beyond. Adv Funct Materials. [DOI: 10.1002/adfm.202112273] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen M, Gilbert N, Liu H. Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway. Reprod Biol Endocrinol 2019;17:86. [PMID: 31656199 DOI: 10.1186/s12958-019-0536-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Geoffroy K, Bourgeois-Daigneault MC. The pros and cons of interferons for oncolytic virotherapy. Cytokine Growth Factor Rev 2020;56:49-58. [PMID: 32694051 DOI: 10.1016/j.cytogfr.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, Ohya K, Teraoka Y, Osawa M, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Abe-Chayama H, Zhang P, Liu S, Makokha GN, Tsuge M, Imamura M, Hayes CN, Chayama K. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. Ther Adv Med Oncol 2020;12:1758835920922051. [PMID: 32547646 DOI: 10.1177/1758835920922051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Khan S, Mahalingam R, Sen S, Martinez-Ledesma E, Khan A, Gandy K, Lang FF, Sulman EP, Alfaro-Munoz KD, Majd NK, Balasubramaniyan V, de Groot JF. Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers (Basel) 2021;13:5284. [PMID: 34771447 DOI: 10.3390/cancers13215284] [Reference Citation Analysis]
12 Mori D, Tsujikawa T, Sugiyama Y, Kotani SI, Fuse S, Ohmura G, Arai A, Kawaguchi T, Hirano S, Mazda O, Kishida T. Extracellular acidity in tumor tissue upregulates programmed cell death protein 1 expression on tumor cells via proton-sensing G protein-coupled receptors. Int J Cancer 2021;149:2116-24. [PMID: 34460096 DOI: 10.1002/ijc.33786] [Reference Citation Analysis]
13 Wu JT, He BW, Cao JL, Yan JB, Chen ZY. Involvement of STING signaling pathway in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(24): 1396-1401 [DOI: 10.11569/wcjd.v29.i24.1396] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer 2019;18:152. [PMID: 31679519 DOI: 10.1186/s12943-019-1087-y] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 19.7] [Reference Citation Analysis]
15 Barley TJ, Murphy PR, Wang X, Bowman BA, Mormol JM, Mager CE, Kirk SG, Cash CJ, Linn SC, Meng X, Nelin LD, Chen B, Hafner M, Zhang J, Liu Y. Mitogen-activated protein kinase phosphatase-1 controls PD-L1 expression by regulating type I interferon during systemic Escherichia coli infection. J Biol Chem 2022;298:101938. [PMID: 35429501 DOI: 10.1016/j.jbc.2022.101938] [Reference Citation Analysis]
16 Farrukh H, El-Sayes N, Mossman K. Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells. Int J Mol Sci 2021;22:4893. [PMID: 34063096 DOI: 10.3390/ijms22094893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
17 Saleiro D, Platanias LC. Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints. Semin Immunol 2019;43:101299. [PMID: 31771762 DOI: 10.1016/j.smim.2019.101299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sawai S, Kishida T, Kotani SI, Tsuchida S, Oda R, Fujiwara H, Takahashi K, Mazda O, Sowa Y. ALK5 i II Accelerates Induction of Adipose-Derived Stem Cells toward Schwann Cells through a Non-Smad Signaling Pathway. Stem Cells Int 2021;2021:8307797. [PMID: 34691193 DOI: 10.1155/2021/8307797] [Reference Citation Analysis]
19 Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, Fuchs SY. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biol Ther 2020;21:629-36. [PMID: 32378445 DOI: 10.1080/15384047.2020.1750297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Shen C, Liu J, Wang J, Zhong X, Dong D, Yang X, Wang Y. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma. Int Immunopharmacol 2020;81:106274. [PMID: 32044664 DOI: 10.1016/j.intimp.2020.106274] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
21 Lee EJ, Jang GY, Lee SE, Lee JW, Han HD, Park YM, Kang TH. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. Immunol Lett 2021;240:137-48. [PMID: 34710507 DOI: 10.1016/j.imlet.2021.10.006] [Reference Citation Analysis]
22 Svanberg C, Nyström S, Govender M, Bhattacharya P, Che KF, Ellegård R, Shankar EM, Larsson M. HIV-1 induction of tolerogenic dendritic cells is mediated by cellular interaction with suppressive T cells. Front Immunol 2022;13:790276. [DOI: 10.3389/fimmu.2022.790276] [Reference Citation Analysis]
23 Fidler G, Szilágyi-Rácz AA, Dávid P, Tolnai E, Rejtő L, Szász R, Póliska S, Biró S, Paholcsek M. Circulating microRNA sequencing revealed miRNome patterns in hematology and oncology patients aiding the prognosis of invasive aspergillosis. Sci Rep 2022;12:7144. [PMID: 35504997 DOI: 10.1038/s41598-022-11239-z] [Reference Citation Analysis]
24 Zhou L, Zhang Y, Wang Y, Zhang M, Sun W, Dai T, Wang A, Wu X, Zhang S, Wang S, Zhou F. A Dual Role of Type I Interferons in Antitumor Immunity. Adv Biosyst 2020;4:e1900237. [PMID: 33245214 DOI: 10.1002/adbi.201900237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Lingling Z, Jiewei L, Li W, Danli Y, Jie Z, Wen L, Dan P, Lei P, Qinghua Z. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology - Research and Practice 2020;216:152852. [DOI: 10.1016/j.prp.2020.152852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Chen C, Yang RX, Xu HG. STING and liver disease. J Gastroenterol 2021;56:704-12. [PMID: 34159442 DOI: 10.1007/s00535-021-01803-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Nakazawa Y, Nishiyama N, Koizumi H, Kanemaru K, Nakahashi-Oda C, Shibuya A. Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. Elife 2021;10:e61999. [PMID: 34751648 DOI: 10.7554/eLife.61999] [Reference Citation Analysis]
28 Burks J, Fleury A, Livingston S, Smith JP. ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression. Cancer Immunol Immunother 2019;68:2029-39. [DOI: 10.1007/s00262-019-02422-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Chan ASH, Kangas TO, Qiu X, Uhlik MT, Fulton RB, Ottoson NR, Gorden KB, Yokoyama Y, Danielson ME, Jevne TM, Michel KS, Graff JR, Bose N. Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies. Front Oncol 2022;12:869078. [DOI: 10.3389/fonc.2022.869078] [Reference Citation Analysis]
30 Brunn D, Turkowski K, Günther S, Weigert A, Muley T, Kriegsmann M, Winter H, Dammann RH, Stathopoulos GT, Thomas M, Guenther A, Grimminger F, Pullamsetti SS, Seeger W, Savai R. Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers (Basel) 2021;13:E208. [PMID: 33430083 DOI: 10.3390/cancers13020208] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Hu Y, Burkard ME. Classes of therapeutics to amplify the immune response. Breast Cancer Res Treat 2021. [PMID: 34787761 DOI: 10.1007/s10549-021-06369-3] [Reference Citation Analysis]
32 Choong WK, Sung TY. Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. iScience 2021;24:102522. [PMID: 34142036 DOI: 10.1016/j.isci.2021.102522] [Reference Citation Analysis]